skip to main content

Tisotumab Vedotin Cervical — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGynaecological CancersTisotumab Vedotin CervicalSCE Medical Oncology

A 55-year-old woman with advanced cervical cancer (PD-L1 CPS ≥1) progresses on first-line pembrolizumab + chemotherapy + bevacizumab. Tisotumab vedotin is considered second-line. What type of drug is tisotumab vedotin?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — An antibody-drug conjugate (ADC) targeting tissue factor (TF) — TF is overexpressed in >90% of cervical cancers; innovaTV 204 showed ORR ~24% in previously treated cervical cancer

Tisotumab vedotin: anti-TF ADC with MMAE payload. Tissue factor expressed >90% cervical cancers. innovaTV 204/301: ORR ~24%, durable responses in heavily pretreated cervical cancer. NICE appraisal pending. Represents first ADC specifically for cervical cancer.

Reference: innovaTV 204/301; ESMO 2024 Cervical